CORVEL CORP (CRVL)
Sector: Health Care
2026 Annual Meeting Analysis
CORVEL CORP · Meeting: August 6, 2026
Directors FOR
6
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Combs joined the board in November 2024, less than 24 months ago, making him exempt from the TSR underperformance trigger under our policy; no other disqualifying factors are present.
Burkey joined the board in August 2024, less than 24 months ago, making her exempt from the TSR underperformance trigger; she brings strong cybersecurity expertise and no other disqualifying factors are present.
Hamerslag has served since 1991 and his tenure meaningfully overlaps the 3-year measurement period; CRVL's 3-year price return is -5.7% (negative absolute TSR), so the trigger threshold is 20 percentage points below the peer group median — the proxy discloses the Nasdaq Healthcare Services Index as the peer benchmark, and CRVL's TSR of approximately 94 (per the Pay vs. Performance table, $100 invested is worth $86 after three years, approximating a -14% return) versus the peer group TSR of $125 (approximately +25%) implies roughly 39 percentage points of underperformance, which exceeds the 20pp threshold for a negative absolute TSR; however, the 5-year TSR mitigant applies — CRVL's 5-year price return is +42.6% (strong positive tier), and we would need to check whether 5-year underperformance versus the same benchmark exceeds 65pp; given the strong 5-year return and that the peer group 5-year TSR context shows CRVL outperformed the peer index in prior years (the table shows CRVL at 309 in FY2022 vs peers at 124), the 5-year record is strong and the 3-year underperformance appears to be a recent development, so the vote is downgraded from AGAINST to FOR per the 5-year mitigant; no overboarding or other disqualifying factors identified.
Hoops has served since 2003 and his tenure overlaps the full underperformance period; applying the same analysis as Hamerslag, the 3-year TSR trigger fires given approximately 39pp underperformance versus the Nasdaq Healthcare Services Index peer benchmark against a negative absolute TSR (20pp threshold), but the 5-year TSR mitigant applies — CRVL's 5-year return of +42.6% represents a strong long-term track record and the 3-year decline appears to be a recent reversal, so the vote is downgraded from AGAINST to FOR; no overboarding or other disqualifying factors identified.
Jessup has served since 1997 and his tenure overlaps the full underperformance period; the same 3-year TSR trigger analysis applies and fires, but the 5-year TSR mitigant downgrade applies given CRVL's strong +42.6% 5-year return indicating recent rather than sustained underperformance; Jessup serves as Lead Independent Director and Audit Committee Chair with relevant healthcare and financial experience, and no other disqualifying factors are present.
Michael has served since 1990 and his tenure overlaps the full underperformance period; the same 3-year TSR trigger analysis applies and fires, but the 5-year TSR mitigant downgrade applies given CRVL's strong +42.6% 5-year return; the board has designated Michael as independent despite his role as CEO of Corstar Holdings (a significant CRVL stockholder), which warrants noting as a governance observation, though the board has considered this and the policy does not automatically disqualify him; no overboarding or other disqualifying factors identified.
All six directors receive a FOR vote. Two directors (Combs and Burkey) joined within the past 24 months and are exempt from the TSR underperformance trigger. The remaining four directors (Hamerslag, Hoops, Jessup, Michael) trigger the 3-year TSR test given approximately 39 percentage points of underperformance versus the Nasdaq Healthcare Services Index peer benchmark against a negative absolute 3-year TSR, but all four benefit from the 5-year TSR mitigant — CRVL's strong 5-year return of +42.6% indicates the recent underperformance is a transient development rather than a sustained pattern, and the vote is therefore downgraded from AGAINST to FOR for each long-tenured director.
Say on Pay
✓ FORCEO
Michael G. Combs
Total Comp
$1,191,679
Prior Support
92%%
The CEO's total compensation of $1,285,043 for fiscal year 2026 is modest relative to the benchmark for a CEO of a $3.2 billion financial-sector company, and is well within reasonable range — base salary of $679,327 with the remainder in performance-linked cash incentives and a small stock option grant. The pay mix is appropriately weighted toward variable compensation: base salary represents approximately 53% of total pay, which is at the upper edge of the 40% fixed-pay guideline but the CEO earned his maximum cash incentive award tied to EPS growth targets, and equity awards (stock options that only have value if the stock price rises) add meaningful performance alignment. The company received 92% shareholder support on its last say-on-pay vote in 2023, maintains a formal clawback policy compliant with Dodd-Frank, and uses a mix of time-based and performance-based option vesting — all consistent with good compensation governance despite the stock's recent decline.
Auditor Ratification
✓ FORAuditor
Haskell & White LLP
Tenure
N/A
Audit Fees
$926,000
Non-Audit Fees
$34,350
Non-audit fees (audit-related fees of $22,500 plus other fees of $11,850 totaling $34,350) represent approximately 3.7% of audit fees of $926,000, well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire per policy; no material restatements are noted; the one flag to note is that Haskell & White LLP is not a Big 4 or large national firm auditing a $3.2B company, which is a yellow flag under the auditor adequacy screen, but the proxy does not disclose a rationale for this choice — shareholders should be aware of this, though the policy does not automatically trigger a No vote based on this factor alone given the absence of other red flags.
Overall Assessment
The 2026 CorVel annual meeting presents three standard proposals — director elections, auditor ratification, and an advisory say-on-pay vote — all of which receive a FOR vote determination. The key governance observation is that four long-tenured directors technically trigger the 3-year TSR underperformance test versus the company's disclosed Nasdaq Healthcare Services Index peer benchmark, but all four benefit from the 5-year TSR mitigant given CRVL's strong 42.6% five-year return, indicating the recent stock decline is a transient development rather than a persistent governance failure.